August 27, 2025 — Leads & Copy — ImmunoPrecise Antibodies Ltd. is advancing to pre-clinical manufacturing for in vivo testing and virus neutralization analysis in its universal dengue vaccine program. The biotherapeutics company is building on June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology.
The manufactured product will be used in proprietary immunization protocols at IPA’s Canadian facility. These studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mAb) responses—a crucial step toward translational development.
According to Dr. Jennifer Bath, CEO of ImmunoPrecise, HYFT technology can identify vaccine targets that others miss, targets that are conserved, specific, and immunologically relevant. By applying the same methodology across pathogens, IPA is positioning its LENSai/HYFT platform as a versatile discovery engine for other infectious diseases and immuno-oncology targets.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.
Dr. Jennifer Bath, CEO of ImmunoPrecise.
Source: ImmunoPrecise Antibodies Ltd.
